Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Analysis of the Primary and Post-Treatment Antibiotic Resistance of Helicobacter pylori in the Nanjing Area

Author(s): Zong-Dan Jiang, Bang-Shun He, Zhen-Yu Zhang*, Shu-Kui Wang*, Dan Ran and Zhi-Bing Wang

Volume 22, Issue 5, 2021

Published on: 22 July, 2020

Page: [682 - 685] Pages: 4

DOI: 10.2174/1389201021666200722162613

Price: $65

Abstract

Background: Resistance of Helicobacter pylori (H. pylori) to antibiotics is increasing worldwide. The study was aimed to understand the current situation of antibiotic resistance in Nanjing and to provide a reasonable basis for clinical selection of antibiotics to cure H. pylori.

Objective: To investigate the current status of H. pylori antibiotics resistance in the Nanjing area, and analyze the primary and post-treatment antibiotic resistance of H. pylori in this area.

Methods: During the period from July 2017 to December 2019, 1533 gastric mucosal specimens from patients with positive H. pylori confirmed by a breath test or rapid urease test were collected for isolation and identification of H. pylori. The agar dilution method was used for the antibiotic resistance test.

Results: The result showed that the resistance rates of H. pylori to amoxicillin, clarithromycin, levofloxacin, furazolidone, tetracycline and metronidazole were 2.74%, 47.03%, 33.59%, 0.91%, 0.52% and 80.76%, respectively in the period of July 2017 to December 2019. The resistance rates of H. pylori (primary vs. post-treatment) to amoxicillin, clarithromycin, levofloxacin, furazolidone, tetracycline and metronidazole were 1.83% vs. 6.08%, 38.62% vs. 77.81%, 27.41% vs. 56.23%, 0.58% vs. 2.13%, 0.33% vs. 1.22%, 78.57% vs. 88.75%, respectively.

Conclusion: Antibiotic resistance of H. pylori remained a problem for the effective eradication of this pathogen and its associated diseases in the Nanjing area. For post-treatment eradication patients, clinicians should take into account regional antibiotic resistance rate, personal antibiotic exposure history, economic benefit ratio, adverse antibiotic reactions, antibiotic availability and other aspects.

Keywords: Helicobacter pylori, the primary and post-treatment antibiotic resistance, Nanjing area, antibiotic availability, adverse antibiotic reactions, antibiotic exposure history.

« Previous Next »
Graphical Abstract

[1]
Moayyedi, P.; Hunt, R.H. Helicobacter pylori public health implications. Helicobacter, 2004, 9(Suppl. 1), 67-72.
[http://dx.doi.org/10.1111/j.1083-4389.2004.00250.x] [PMID: 15347308]
[2]
Duck, W.M.; Sobel, J.; Pruckler, J.M.; Song, Q.; Swerdlow, D.; Friedman, C.; Sulka, A.; Swaminathan, B.; Taylor, T.; Hoekstra, M.; Griffin, P.; Smoot, D.; Peek, R.; Metz, D.C.; Bloom, P.B.; Goldschmidt, S.; Parsonnet, J.; Triadafilopoulos, G.; Perez-Perez, G.I.; Vakil, N.; Ernst, P.; Czinn, S.; Dunne, D.; Gold, B.D. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis., 2004, 10(6), 1088-1094.
[http://dx.doi.org/10.3201/eid1006.030744] [PMID: 15207062]
[3]
Malfertheiner, P.; Chan, F.K.; McColl, K.E. Peptic ulcer disease. Lancet, 2009, 374(9699), 1449-1461.
[http://dx.doi.org/10.1016/S0140-6736(09)60938-7] [PMID: 19683340]
[4]
Moore, J.M.; Salama, N.R. Mutational analysis of metronidazole resistance in Helicobacter pylori. Antimicrob. Agents Chemother., 2005, 49(3), 1236-1237.
[http://dx.doi.org/10.1128/AAC.49.3.1236-1237.2005] [PMID: 15728938]
[5]
Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Atherton, J.; Axon, A.T.; Bazzoli, F.; Gensini, G.F.; Gisbert, J.P.; Graham, D.Y.; Rokkas, T.; El-Omar, E.M.; Kuipers, E.J. European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut, 2012, 61(5), 646-664.
[http://dx.doi.org/10.1136/gutjnl-2012-302084] [PMID: 22491499]
[6]
Xie, C.; Lu, N.H. Review: clinical management of Helicobacter pylori infection in China. Helicobacter, 2015, 20(1), 1-10.
[http://dx.doi.org/10.1111/hel.12178] [PMID: 25382801]
[7]
Hu, Y.; Zhu, Y.; Lu, N.H. Primary antibiotic resistance of Helicobacter pylori in China. Dig. Dis. Sci., 2017, 62(5), 1146-1154.
[http://dx.doi.org/10.1007/s10620-017-4536-8]
[8]
Liu, W.Z.; Xie, Y.; Lu, H.; Cheng, H.; Zeng, Z.R.; Zhou, L.Y.; Chen, Y.; Wang, J.B.; Du, Y.Q.; Lu, N.H. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter, 2018, 23(2)e12475
[http://dx.doi.org/10.1111/hel.12475] [PMID: 29512258]
[9]
Su, P.; Li, Y.; Li, H.; Zhang, J.; Lin, L.; Wang, Q.; Guo, F.; Ji, Z.; Mao, J.; Tang, W.; Shi, Z.; Shao, W.; Mao, J.; Zhu, X.; Zhang, X.; Tong, Y.; Tu, H.; Jiang, M.; Wang, Z.; Jin, F.; Yang, N.; Zhang, J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter, 2013, 18(4), 274-279.
[http://dx.doi.org/10.1111/hel.12046] [PMID: 23418857]
[10]
Graham, D.Y.; Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 2010, 59(8), 1143-1153.
[http://dx.doi.org/10.1136/gut.2009.192757] [PMID: 20525969]
[11]
Zheng, Q.; Chen, W.J.; Lu, H.; Sun, Q.J.; Xiao, S.D. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J. Dig. Dis., 2010, 11(5), 313-318.
[http://dx.doi.org/10.1111/j.1751-2980.2010.00457.x] [PMID: 20883428]
[12]
Malfertheiner, P.; Bazzoli, F.; Delchier, J.C.; Celiñski, K.; Giguère, M.; Rivière, M.; Mégraud, F. Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet, 2011, 377(9769), 905-913.
[http://dx.doi.org/10.1016/S0140-6736(11)60020-2] [PMID: 21345487]
[13]
Graham, D.Y.; Rimbara, E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J. Clin. Gastroenterol., 2011, 45(4), 309-313.
[http://dx.doi.org/10.1097/MCG.0b013e31820ac05e] [PMID: 21389810]
[14]
Rimbara, E.; Fischbach, L.A.; Graham, D.Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(2), 79-88.
[http://dx.doi.org/10.1038/nrgastro.2010.210] [PMID: 21293508]
[15]
Zhang, Y.X.; Zhou, L.Y.; Song, Z.Q.; Zhang, J.Z.; He, L.H.; Ding, Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J. Gastroenterol., 2015, 21(9), 2786-2792.
[http://dx.doi.org/10.3748/wjg.v21.i9.2786] [PMID: 25759550]
[16]
Correa, P.; Piazuelo, M.B. Natural history of Helicobacter pylori infection. Dig. Liver Dis., 2008, 40(7), 490-496.
[http://dx.doi.org/10.1016/j.dld.2008.02.035] [PMID: 18396115]
[17]
Khan, A.; Farooqui, A.; Raza, Y.; Rasheed, F.; Manzoor, H.; Akhtar, S.S.; Quraishy, M.S.; Rubino, S.; Kazmi, S.U.; Paglietti, B. Prevalence, diversity and disease association of Helicobacter pylori in dyspeptic patients from Pakistan. J. Infect. Dev. Ctries., 2013, 7(3), 220-228.
[http://dx.doi.org/10.3855/jidc.2942] [PMID: 23493000]
[18]
Thung, I.; Aramin, H.; Vavinskaya, V.; Gupta, S.; Park, J.Y.; Crowe, S.E.; Valasek, M.A. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther., 2016, 43(4), 514-533.
[http://dx.doi.org/10.1111/apt.13497] [PMID: 26694080]
[19]
Song, Z.; Zhang, J.; He, L.; Chen, M.; Hou, X.; Li, Z.; Zhou, L. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig. Liver Dis., 2014, 46(12), 1077-1081.
[http://dx.doi.org/10.1016/j.dld.2014.08.038] [PMID: 25220697]
[20]
Ji, Z.; Han, F.; Meng, F.; Tu, M.; Yang, N.; Zhang, J. The Association of age and antibiotic resistance of Helicobacter Pylori: a study in Jiaxing City, Zhejiang province China. Medicine (Baltimore), 2016, 95(8)e2831
[http://dx.doi.org/10.1097/MD.0000000000002831] [PMID: 26937912]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy